If you’re checking the zyxi stock price today, you aren’t just looking at a ticker symbol; you’re looking at a cautionary tale about how fast a medical technology darling can fall. Honestly, it’s a mess.
As of January 17, 2026, Zynex Inc. (now trading under the symbol ZYXIQ on the OTC markets) is a shadow of the company that once dominated the non-opioid pain management space. The stock is currently hovering around $0.087, a staggering drop from the double-digit prices investors saw just a couple of years ago. It’s a penny stock now. Actually, it’s less than a dime.
The story of Zynex over the last twelve months is basically a masterclass in what happens when regulatory hurdles, payment suspensions, and debt all hit the fan at the exact same time.
Why the ZYXI Stock Price Today Looks So Different
Most investors remember Zynex as the high-flying manufacturer of the NexWave electrotherapy device. They were the "anti-opioid" play. But the zyxi stock price today reflects a company that filed for bankruptcy protection in December 2025. You’ve probably noticed the "Q" added to the end of the ticker symbol. That’s the scarlet letter of the stock market—it signifies that the company is currently in bankruptcy or reorganization proceedings.
The downfall wasn't a slow burn; it was more like a cliff.
It really started with Tricare. For years, Tricare was a massive part of Zynex’s revenue stream. When Tricare suspended payments and changed their claim submission practices, the air was sucked out of the room. By the time Q3 2025 results were released in November, the damage was undeniable. Revenue had cratered to just $13.4 million, compared to $50 million in the same quarter the previous year.
A 73% revenue drop? You don't just "bounce back" from that without some serious scars.
The Numbers That Broke the Back of the Stock
- Net Loss: In Q3 2025 alone, Zynex posted a net loss of $42.9 million. That’s $1.42 per share. To put that in perspective, analysts were only expecting a loss of about $0.17. They missed by over 700%.
- The Debt Bomb: The company is sitting on $60 million in convertible notes that are set to mature in May 2026.
- Cash Reserves: As of late 2025, they only had about $13.3 million in cash left.
When you have $13 million in the bank and $60 million in debt due in a few months, while losing $40 million a quarter, the math simply doesn't work. Management tried to pivot. They hired Province, LLC to look for "strategic alternatives"—which is corporate-speak for "someone please buy us or help us find a way not to go under." They even skipped a $1.5 million interest payment in November to preserve what little cash they had left.
Understanding the Bankruptcy and OTC Transition
When Zynex moved from the NASDAQ to the OTC Markets (the "pink sheets"), the zyxi stock price today became much more volatile. Institutional investors usually aren't allowed to hold stocks that trade on the OTC. So, when the delisting happened in late 2025, a massive wave of forced selling hit the market.
That’s why you see these wild percentage swings now. On any given day, the stock might jump 20% or drop 15%, but because the price is only a few cents, those moves are often driven by retail speculation rather than actual business improvements.
Is There Any Path Forward?
Kinda. But it's a long shot.
The new CEO, Steven Dyson, who took over in August 2025, has been trying to lean into a three-part strategy: compliance, liquidity, and revenue improvement. They are working with an ad hoc group of noteholders to restructure that $60 million debt. If they can swap that debt for equity or push the maturity date back, there’s a slim chance the company survives as a leaner, private entity or a much smaller public one.
However, for current common shareholders, the news is usually grim in these situations. In a bankruptcy restructuring, the "people in line" for money are:
- The IRS and employees.
- Secured lenders.
- Bondholders (the people holding that $60 million in notes).
- Common shareholders (You).
Usually, by the time the bondholders get paid, there’s nothing left for the people holding the stock.
What to Watch Next for Zynex
If you're tracking the zyxi stock price today and wondering if it's a "buy the dip" opportunity, you need to be extremely careful. This isn't a dip; it's a restructuring.
The next big date on the calendar is February 26, 2026. That’s when the company is expected to report its Q4 2025 earnings. While most people are looking at the revenue (projected at roughly $21.4 million), the real thing to watch is the commentary on the debt restructuring. If they haven't reached a deal with the noteholders by then, the "Q" might stand for "Quietly fading away."
Actionable Insights for Investors
- Check the Ticker: Make sure you are looking at ZYXIQ, not just ZYXI. Most major brokers will charge extra fees for trading OTC stocks, or they might not let you buy them at all.
- Ignore the "Percent Gains": A 25% gain on a $0.07 stock is less than two cents. Don't let the green bars on your screen fool you into thinking the business has recovered.
- Read the 8-K Filings: In a bankruptcy, the SEC filings are your only source of truth. Look for "Entry into a Material Definitive Agreement" which would signal a deal with creditors.
- Recognize the Risk: At this stage, ZYXIQ is closer to a lottery ticket than an investment. Only put in money you are 100% prepared to lose by tomorrow morning.
The reality is that Zynex’s flagship NexWave device is still liked by doctors. The product itself isn't the problem—it's the balance sheet and the reimbursement environment. Until the company solves the $60 million debt problem, the zyxi stock price today will likely continue to reflect a high-risk, speculative environment.
Keep a close eye on the Special Committee’s announcements regarding capital raising. Any new "strategic transaction" will likely dilute current shareholders significantly, but it might be the only way the company avoids total liquidation.
